abnormal procainamide pharmacokinetics ( prolonged half-life and decreased volume of distribution ) and pharmacodynamics ( decreased threshold for the suppression of premature ventricular complexes ) have been suggested in patients with acute myocardial infarction or congestive heart failure , or both .
C0033216
procainamide
C0151636
premature ventricular complexes